Abstract. The scaffold protein IQGAP1 is closely related to certain Rho GTPases. Research has revealed that IQGAP1 acts as an effector of Cdc42 and Rac1 in the regulation of cell activity such as proliferation and migration. However, whether IQGAP1 is associated with RhoC, another important Rho GTPase, is unclear. Previous results from our laboratory indicated that IQGAP1 and RhoC are highly expressed in gastric cancer tissues and cells. This study was designed to investigate the possible interaction between IQGAP1 and RhoC in the regulation of the migration of cancer cells. The expression of IQGAP1 and RhoC in gastric cancer tissues and cell lines was detected by Western blotting. siRNAs targeting IQGAP1 or RhoC were transfected into gastric cancer cells to knock down the expression of the proteins. Adenoviral constructs encoding full length IQGAP1, the C-terminal fragment of IQGAP1, and the constitutively active RhoC gene were used to infect gastric cancer cells to increase the expression of the proteins. The migratory activity of a gastric cancer cell line was measured by a transwell migration assay. Western blotting revealed that the IQGAP1 and RhoC proteins were highly expressed in gastric cancer tissues and cells. Spearman's rank correlation analysis indicated that the increases in the expression of IQGAP1 and RhoC were closely correlated. The transwell migration assay revealed that both IQGAP1 and RhoC stimulated the migration activity of the gastric cancer cell line AGS. The knockdown of IQGAP1 expression by siRNA blocked the migration-stimulating activity of RhoC, while the knockdown of RhoC expression had no effect on the migration-stimulatory activity of IQGAP1. Co-IP results showed that RhoC and IQGAP1 bound to each other. These results reveal a previously unrecognized interaction between IQGAP1 and RhoC, and demonstrate that IQGAP1 is a downstream effector of RhoC in the regulation of the migration activity of gastric cancer cells.
Introduction
Ras GTPase-activating-like proteins (IQGAPs) are evolutionary conserved multi-domain proteins that share a similar domain structure and a marked sequence homology. To date, three IQGAPs have been identified in humans. Among them, the best-characterized is IQGAP1, which contains a calponinhomology domain, a tryptophan repeat motif, four centrally located IQ motifs, a C-terminal RasGAP-related domain and a RasGAP-C-terminal domain. As a scaffold protein, IQGAP1 binds multiple proteins and facilitates their interaction. Research has shown that IQGAP1 interacts directly with calmodulin (1), actin (2) , E-cadherin (3, 4) , β-catenin (5) , and the small GTPases Cdc42 (3), Rac1 (6) and Rap1 (7, 8) . Through its interaction with these proteins, IQGAP1 regulates many cellular functions including cell-cell adhesion, migration (9) , cytoskeletal architecture (10), transcription (11) and selected signal transductions.
IQGAP1 has been implicated in tumorigenesis due to the observed overexpression and altered localization of IQGAP1 in neoplasia, particularly at the peripheral regions of more aggressive breast cancer (12) , colorectal carcinoma (13) and ovarian adenocarcinomas (14) . A lack of IQGAP1 expression is associated with a favorable prognosis in gastric cancer (15) . Furthermore, IQGAP1 assists in various signal transductions implicated in cancer. For example, IQGAP1 interacts with MEK, ERK (16) and B-Raf (1) to facilitate their sequential activation and to stimulate MAPK-mediated signaling (17) , and promotes proliferation or differentiation (3) . IQGAP1 is also capable of directly associating with β-catenin (18) , an oncogenic protein and primary mediator of the Wnt pathway, to cause cell transformation, invasion and migration. Emerging evidence supports a potential role of IQGAP1 in regulating protein traffic (19) , cell proliferation and division (20) via the CDC42-mTOR pathway. In another study, it was demonstrated that IQGAP1 facilitated mTOR and Akt interaction and promoted cell proliferation by PI3K/Akt signaling in hepatocellular carcinoma (21) . However, although there are adequate data supporting the role of IQGAP1 in tumor progression, what triggers its up-regulation and what key binding partners augment its role in tumorigenicity remain to be determined.
The Rho family of GTPase belongs to the Ras super-family of small G proteins, which currently comprises more than 20 members. Among them, RhoA, RhoB, and RhoC are grouped into the Rho subclass. Recent studies have revealed that RhoA and RhoB appear to be associated with the proliferation of cancer cells; nevertheless the overexpression of RhoC enhances the metastasis of cancer cells (22, 23) . RhoC is frequently overexpressed in a variety of human tumors, and the degree of overexpression correlates with tumor progression and clinical outcome in some cases, such as breast cancer (24) , pancreatic cancer (25) , colon cancer (26) , bladder cancer, hepatocellular carcinoma, non-small cell lung carcinoma (27) and primary gastric tumors (23) . In brief, research suggests that RhoC is correlated with tumorigenesis, development and the infiltration metastasis of certain tumor types (28) ; however, the mechanisms of its action have yet to be elucidated.
IQGAP1 is closely related to some GTPases of the Rho family. For example, both Cdc42 and Rac1, key members of the other two subclasses of the Rho family, interact with IQGAP1 to stimulate the motility of cells. Recently, researchers also observed that Rap1b (7, 8) was co-localized with IQGAP1, facilitated the sequential phosphorylation of B-Raf, C-Raf, and ERK1/2, and aided IQGAP1 to form a large signalosome in the perinuclear region. Among the members of the Rho subclass, RhoA (29) has been revealed to have no interaction with IQGAP1. However, it remains to be determined whether RhoC is associated with IQGAP1 or not. Based on our previous observation that the expression of IQGAP1 and RhoC in gastric cancer tissues was markedly higher than that in non-neoplasia mucosa tissues, here we investigated the possible association between IQGAP1 and RhoC.
Materials and methods
Tissue samples. Gastric cancer tissue specimens (n=29) were obtained from patients who had undergone surgical resection at the Department of Surgery, Affiliated Hospital of Jiangsu University. None received preoperative chemotherapy or radiotherapy. Fresh specimens were removed from the resected tissues and were immediately frozen at -80˚C and stored until use. The corresponding non-neoplasia mucosa tissues, resected at least 5 cm away from the tumor margin, served as controls. All patients provided written informed consent, and the study protocol and patient information sheets were approved by the Ethics Committee of Jiangsu University. Reagents, antibodies, siRNA and plasmids. Dulbecco's modified Eagle's medium (DMEM) and fetal bovine serum (FBS) were from Gibco (Grand Island, NY, USA). Lipofectamin™ 2000 cell transfection reagent was from Invitrogen (Carlsbad, CA, USA); mouse anti-RhoC antibody was from Abcam (Cambridge, MA, USA); horseradish peroxidase (HRP)-conjugated secondary antibody was from Rockland Immunochemicals (Gilbertsville, PA, USA); mouse anti-IQGAP1 antibody (against a Glu-Glu tagged C-terminal fragment corresponding to amino acids 863-1657 of human IQGAP1) was from Millipore (Billerica, MA, USA); goat anti-β-action antibody, and short-interfering RNAs (siRNA) for RhoC and the negative control were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The siRNA for IQGAP1 was synthesized by Qiagen (Valencia, CA, USA) with a target sequence of 5'-AAGTTCTACGGGAAGTAATTG-3' (5058-5078 bp). Electrochemiluminescence (ECL) reagents were from Millipore; the adenoviral vectors pAd-LacZ (encoding β-galactosidase), pAd-RhoC-V14 (encoding a constitutive active form of RhoC), pAd-IQGAP1 (encoding the full length IQGAP1) and pAd-IQGAP1-C (encoding the C-terminal fragment of IQGAP1, amino acids 860-1657) were kind gifts from Dr Renate Pilz of the University of California, San Diego, USA; all other reagents used were of analytical grade.
Cell culture, transfection and RNA interference. BGC-823, AGS, GES-1, SGC-7901 and COS-7 cells were cultured in 1X DMEM containing 10% FBS at 37˚C in a 5% CO 2 atmosphere. The medium was changed every second day and the cells were sub-cultured at confluence. For transfection, the cells were sub-cultured the day before the process. The seeding amount of cells was adjusted to attain a density of 30-50% confluence on the day of transfection. Transfection of gastric cancer cells with siRNA was performed using Lipofectamin 2000. After 4-6 h, the siRNA/lipid complexes were removed, and the cells were maintained in complete medium for an additional 48-72 h. The inhibition of protein expression was determined by Western blotting.
Western blotting. Cultured cells were washed three times in phosphate-buffered saline (PBS) and lysed with RIPA buffer (50 mM Tris-HCl pH 7.4, 1% (v/v) Triton X-100, 1 mM EDTA, 1 mM leupeptin, 1 mM PMSF, 10 mM NaF, 1 mM Na 3 VO 4 ). Frozen samples of human gastric cancer tissue and normal mucosa tissue were thawed and homogenized in the same buffer. Equal amounts of protein were accumulated with a voltage of 8 V/cm and separated with a voltage of 15 V/cm on the gel. After electrophoresis, the proteins on the gel were transferred to a polyvinyl difluoride (PVDF) membrane. The membrane was incubated with mouse anti-RhoC antibody 
A C B D
(diluted 1:500) or mouse anti-IQGAP1 antibody (diluted 1:1000), followed by incubation with the corresponding secondary antibodies. ECL reagents were used to develop the positive bands on the membrane.
Co-immunoprecipitation.
To investigate the interaction between IQGAP1 and RhoC, COS-7 cells that had been co-infected for 48 h with pAd-IQGAP1 and RhoC-V14 or pAd-IQGAP1-C and RhoC-V14 were lysed with RIPA buffer as described. Antibodies against RhoC and IQGAP1 and isotype matched IgG were used for immunoprecipitation and immunoblotting assay.
Transwell migration assays. Cell migration assays were performed using transwell cell migration chambers (24-well inserts, 8-µm pore size; Costar) according to the manufacturer's instructions. AGS cells were transfected with siRNAs targeting IQGAP1 or RhoC for 24 h and then infected with pAd-RhoC-V14, pAd-IQGAP1-C or pAd-IQGAP1 for an additional 48 h. The cells were serum-starved for 12 h and then trypsinized, washed, counted, and re-suspended at 2x10 4 cells per well in 300 µl of medium containing 0.5% FBS, and placed in the upper compartment of the chamber. The lower compartment was filled with 500 µl of medium containing 10% FBS. After incubating for 12 h at 37˚C, the cells remaining in the upper chamber were carefully removed with cotton swabs. Migrated cells on the lower membrane surface were fixed with 4% paraformaldehyde (PFA) and stained with Giemsa staining solution (1:20 in H 2 O). In each chamber, cells in five randomly selected high-power (x200) fields were counted and the mean was taken as migration value of this chamber.
Statistical analysis. The data were expressed as the means ± standard deviation (SD). Statistical significance was performed using two-tailed ANOVA or the Student's t-test with SPSS statistical software. The correlation between IQGAP1 and RhoC was analyzed by Spearman's rank correlation. A p-value <0.05 was considered significant.
Results

Increased expression of IQGAP1 and RhoC in gastric cancer
tissues and cell lines. In 22 of 29 pairs of samples (75.9%), the expression levels of IQGAP1 and RhoC were higher in gastric cancer tissues than in non-neoplastic mucosa tissues (p<0.05; Fig. 1A and B; Table Ⅰ) . Correlation analysis by the Spearman's rank test revealed a direct correlation between the expression levels of IQGAP1 and RhoC in gastric cancer tissues (p=0.004, r=0.521; Table I ). In the cell lines, both IQGAP1 and RhoC protein expression levels were increased in the gastric cancer cell lines BGC-823, AGS and SGC-7901 as compared with the human gastric epithelial cell line GES-1 (Fig. 1C and D) .
Stimulation of the migration of gastric cancer cells by IQGAP1
and RhoC. The effect of IQGAP1 on cell migration was evalu- ated by a transwell migration assay. The results revealed that increased expression of full length IQGAP1 (pAd-IQGAP1) or the C-terminal fragment of IQGAP1 (pAd-IQGAP1-C) accelerated cell migration (p<0.05; Fig. 2A and B) . By contrast, reduction of endogenous IQGAP1 by siRNA attenuated cell migration by 50% (p<0.05; Fig. 2C and D) . On the other hand, the results revealed that RhoC also stimulated the migration of gastric cancer cells. Overexpression of the constitutively active form of RhoC (pAd-RhoC-V14) in AGS cells enhanced migration ( Fig. 3A and B) . The depletion of RhoC by siRNA inhibited the migration of AGS cells (Fig. 3C and D) .
Blockade of RhoC migration-stimulating effect by interference with IQGAP1 expression.
Since RhoC and IQGAP1 were highly expressed in gastric cancer tissues and cell lines and stimulated the migration of the gastric cancer cell line AGS, we employed several strategies to investigate the possible association between the two proteins. First, AGS cells were transfected with siRNA interfering with the expression of RhoC or IQGAP1, and then infected with adenoviral vector encoding IQGAP1, IQGAP1-C or constitutively active RhoC to determine whether increasing or decreasing one protein would affect the expression of the other. The results revealed that exogenous expression or knockdown of one protein did not significantly affect the expression of the other protein (Fig. 4A) . Next, we examined the effect of RhoC knockdown on cell migration stimulated by the full length IQGAP1 or C-terminal fragment of IQGAP1. As shown in Fig. 4B , cell migration was still enhanced in RhoC-siRNA-depletion gastric cancer cells overexpressing the IQGAP1 or IQGAP1 C-terminal fragment ( ** p<0.01). On the other hand, we also tested whether the knock down of IQGAP1 blocked the stimulatory effect of RhoC on cell migration. Fig. 4C showed that the depletion of IQGAP1 by siRNA significantly suppressed the migration enhanced by constitutively active RhoC in gastric cancer cells ( * p<0.05, ** p<0.01). These data indicated that IQGAP1 served as a downstream effector of RhoC in stimulating the migration of gastric cancer cells, and that the C-terminal fragment of IQGAP1 was the effective region of the protein in association with RhoC. RhoC and IQGAP1 bind to each other. The co-immunoprecipitation method was used to investigate whether RhoC and IQGAP1 bound to each other. In one group, COS-7 cells were co-infected with pAd-IQGAP1 and pAd-RhoC-V14 for 48 h, and the total cell lysate was immunoprecipitated with anti-RhoC antibody and probed with antibody against IQGAP1. In another group, COS-7 cells were co-infected with pAd-IQGAP1 and RhoC-V14 for 48 h, and the total cell lysate was immunoprecipitated with anti-IQGAP1 antibody and probed with antibody against RhoC. The results revealed that RhoC and IQGAP1 bound to each other (Fig. 5A) . To further confirm whether the C-terminal fragment of IQGAP1 was the binding site with RhoC, COS-7 cells were co-infected with pAd-IQGAP1-C and pAd-RhoC-V14 for 48 h, and the total cell lysate was immunoprecipitated with anti-RhoC or anti-IQGAP1 antibodies, respectively. As shown in Fig. 5B , RhoC also bound to the C-terminal fragment of IQGAP1. Together, these data indicate a previously unknown interaction between IQGAP1 and RhoC, and the C-terminal fragment of IQGAP1 as the binding site with RhoC.
Discussion
Metastasis is the main cause of cancer patient mortality, and the mechanism of metastasis has attracted much research interest. Cell migration is closely related to cancer metastasis, and complex interactions among various proteins and signaling pathways contribute to this process. Rho GTPases have been postulated to participate in regulating migration. For example, Cdc42 and Rac1, two key subclasses of the Rho GTPase family, play important roles in the progression of migration/metastasis (30) . RhoC, a key member of the Rho family, is up-regulated in many types of cancer, and the increased expression of RhoC is correlated with progression and poor prognosis in some types (30) (31) (32) . The cumulative evidence indicates a significant function of RhoC in the malignant progression of neoplasia, including invasion (33), epithelial-to-mesenchymal transition (EMT) (34), metastasis and proliferation (35) . Our results revealed that RhoC was highly expressed in gastric cancer tissues and cell lines, and that the high expression of RhoC was correlated with the poor differentiation and high invasion of the cancer cells (data not shown). These results are consistent with results from other labs, and further support the involvement of RhoC in the progression of cancer. As a scaffold protein, IQGAP1 promotes cell proliferation and motility by binding multiple proteins and regulating their functions. Studies have revealed that, in gastric cancer cells, the overexpression of IQGAP1 enhances cell invasion, while specific knockdown of endogenous IQGAP1 by siRNA significantly reduces cell motility (36) . Studies have also indicated that elevated IQGAP1 levels are correlated with the increased expression of certain Rho GTPases, such as active Cdc42 and Rac1 (37, 38) . In our study, we investigated the expression of IQGAP1 and RhoC in the same clinical samples and found that IQGAP1 and RhoC were highly expressed in cancer tissues. More significantly, our results revealed that changes in the expression of IQGAP1 and RhoC were closely correlated. This indicates that IQGAP1 and RhoC may have a close association/interaction in cancer progression, particularly in regulating migration/metastasis. Through a transwell migration assay, we investigated the migration-stimulatory effect of IQGAP1 and RhoC on gastric cancer cells. Our results revealed that the induction of IQGAP1 and RhoC expression through infection with adenoviral constructs stimulated the migration of the gastric cancer cell line AGS, and that the siRNA-mediated knockdown of IQGAP1 and RhoC expression inhibited the cell traits. In regulating migration, the knockdown of IQGAP1 expression blocked the migration-stimulating effect of RhoC, while that of RhoC expression did not block the migration-stimulating effect of full length IQGAP1 or the C-terminal fragment of IQGAP1. This indicates that IQGAP1, specifically the C-terminal fragment of IQGAP1, and RhoC were associated with the regulation of migration, and that IQGAP1 may be a downstream effector of RhoC. Through a co-immunoprecipitate assay, we not only observed direct binding between the full length IQGAP1 and RhoC molecules, but also found that it was the C-terminal fragment of IQGAP1 that bound with RhoC, similar to the binding between IQGAP1 and Cdc42 (20, 29) . Collectively, these data reveal for the first time an association between RhoC and IQGAP1, and suggest that IQGAP1 is a downstream effector of RhoC during the regulation of cell migration.
In conclusion, we confirm the effect of IQGAP1 and RhoC on migration in gastric cancer cells, and reveal for the first time the interaction between the two proteins. This will aid in the further understanding of the mechanisms of the migration and metastasis of cancer cells, and suggests novel strategies for cancer therapy.
